Havn Life Sciences Inc · CSE:HAVN
Havn Life Sciences — Investor Presentation (April 2022)
28 slides from Havn Life Sciences's investor presentation, April 2022
Slide 1: The Future of Psychedelic Therapy
The Future of Psychedelic Therapy FOCUSED ON THE RAPIDLY GROWING FIELD OF FUNCTIONAL MUSHROOMS, NATURAL HEALTH PRODUCTS & PSYCHEDELIC MEDICINE CSE: HAVN | FRA: 5NP | OTC: HAVLF
Slide 2: Investment Highlights
INVESTMENT HIGHLIGHTS This presentation is confidential and is being issued by HAVN Life (the “Company”) for informational purposes only. other advisors to determine the risks and consequences of an investment in the Company. Prospective investors Reliance on this presentation for the purpose of eng
Slide 3: Mission
MISSION Our mission is to unlock human performance & increased cognitive health using evidence-informed research We are focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from novel compounds Inv
Slide 4: Who We Are Today
WHO WE ARE TODAY HAVN Labs is creating the opportunity to lead in HAVN Retail focuses on the development and the standardization of naturally based ingredient standardization of natural health products that supply for a growing industry of psychedelic support the brain medicine for the treatment of
Slide 5: We Operate Two Distinct Business Units
WE OPERATE TWO DISTINCT BUSINESS UNITS HAVN RETAIL HAVN LABS Natural Health Psychedelic Products Extraction and Supply HAVN Life Contract Supply Academic Formulate Microdosing Brands Manufacturer Research Therapies (White Label) (Dealers License) (Pre-Clinical Trials) Retail Online Investor Deck 5 2
Slide 6: HAVN Retail
HAVN RETAIL O LIFE
Slide 7: 11 Commercial Products - More on the Way
11 COMMERCIAL PRODUCTS - MORE ON THE WAY 7 Plant and 4 Patented Functional Mushroom Traumatic Brain Extracts Provide Injury Products Increased mindfulness Improves sleep Decreased stress Reduces inflammation and anxiety Increase energy Improved immunity & improve memory Our natural health products a
Slide 8: Designed with Human Optimization in Mind
DESIGNED WITH HUMAN OPTIMIZATION IN MIND We have developed a line of naturally-derived formulations to support mental health and performance MIND BACOPA RHODIOLA CORDYCEPS CHAGA REISHI LION’S MUSHROOM BRAIN RELIEF PERFORM IMMUNITY RECHARGE MANE Immune system Memory and Improve mental Energy and Anti
Slide 9: New Patented Brain Health Solutions
NEW PATENTED BRAIN HEALTH SOLUTIONS Designed to support, protect and enhance your lifestyle MENTAL ACUITY TRAUMATIC BRAIN INJURY COGNITIVE ENERGY SLEEP HEALTH FOCUS MAINTENANCE Flavoured Unflavoured Investor Deck 9 2022
Slide 10: Key Benefits and Features
KEY BENEFITS AND FEATURES KEY BENEFITS KEY FEATURES • Promotes Deep Sleep • Patented Formulations • Increased Energy • Health Canada Approved • Mood Balance • Practitioner Formulated • Reduces Inflammation • Third Party Tested • Trauma Recovery • Carried at GNC stores across Canada • Brain Regenerat
Slide 11: Our Supplement Market
OUR SUPPLEMENT MARKET What's in supplements matters of consumers take a 74% and customers are starting to care supplement with that percentage increasing BRAIN POWER ever year The global pandemic created an unprecedented surge in demand for products addressing immunity By 2027 (5) and cognitive supp
Slide 12: Sales and Marketing Strategy
SALES AND MARKETING STRATEGY At HAVN Life we've implemented We've developed best in class SEO smart, pragmatic, and engaging strategies to make HAVN Life easy to find for communication with our primary target consumers looking to find sustainable, audience, our retail partners, and our accessible, c
Slide 13: HAVN Labs
HAVN The next big development in mental healthcare may come in the form of psychedelic drugs: substances such as psilocybin (magic mushrooms), LABS ayahuasca (a plant-based mixture from South America), and DMT (a naturally occurring hallucinogenic) While these substances have been illegal and primar
Slide 14: A New Era for Mental Health
A NEW ERA FOR MENTAL HEALTH Global productivity and mental health are on the rise and our current treatments are not where they need to be to support human optimization. MILLION TRILLION 350 PEOPLE 1 LOST >50% globally affected by annually in global workforce non-adherence to a form of depression pr
Slide 15: Behavioural Health Market Opportunity
BEHAVIOURAL HEALTH MARKET OPPORTUNITY The behavioral health market And right now 2/3 is expected to be valued at of Canadian military personnel with PTSD do 240 BILLION BY 2026 not respond completely to the best available care. HAVN Labs will work with veterans and PTSD groups across North America t
Slide 16: What Is Microdosing?
RETHINK WHAT IS MICRODOSING? Microdosing is a process whereby small doses of a psychoactive compound, typically psychedelics are used. Each Rethink how we treat mental health dose has the benefits of the psychoactive compound without affecting your day to day functioning which means you are able We
Slide 17: The Psychedelic Ecosystem
THE PSYCHEDELIC ECOSYSTEM Today there are three major groups using Psychedelics PSYCHEDELIC RETREATS • Retreats that last days or weeks run in a safe and controlled manner in jurisdictions where currently legal, e.g. Jamaica, Netherlands, Costa Rica • Use various plant medicines to assist optimal he
Slide 18: Current Landscape of Clinical Programs Advancing Psychedelic Medicine
CURRENT LANDSCAPE OF CLINICAL PROGRAMS ADVANCING PSYCHEDELIC MEDICINE Psychedelic research has over 50 years of history Psychedelic research has been conducted by well Presently there are ongoing clinical trials respected institutions including Johns Hopkins, focusing NYU, King's College, University
Slide 19: State-of-the-Art GMP Mycology Lab for Psychedelic Extraction
STATE-OF-THE-ART GMP MYCOLOGY LAB FOR PSYCHEDELIC EXTRACTION Working in cooperation with Minister of Agriculture in Jamaica Cultivating mushrooms under GACP(Good Agricultural and Collection Practices) and processing in GMP facility for export Scalable production capabilities to match current and fut
Slide 20: Current Evolving Regulatory Environment
CURRENT EVOLVING REGULATORY ENVIRONMENT Psilocybin is not illegal, it is highly regulated, like guns, alcohol and tobacco Countries like Jamaica, Costa Rica, Netherlands have legalized some psychedelics In the US, the city of Denver decriminalized psilocybin mushrooms. It was quickly followed by Oak
Slide 21: The Unit Economics of Being a Natural Ingredient Supplier
THE UNIT ECONOMICS OF BEING A NATURAL INGREDIENT SUPPLIER Synthetic psilocybin is priced at Naturally derived is much less USD7000 to USD10,000 per gram. expensive to produce and can ($10 million per kg) translating to be supplied at a lower cost while $175 to $250 per 25 mg dose still generating at
Slide 22: Supply Agreements - Jamaica
SUPPLY AGREEMENTS Jamaica While awaiting approval of our Dealers License in Canada, we are validating our processes and protocols at a facility in Jamaica, where psilocybin is not a restricted compound. Our fully operational facility in Kingston allows us to move along the learning curve and provide
Slide 23: Comparables
COMPARABLES In CDN $, where applicable Company Ticker Stock Price (1) Market Cap LTM Revenue Market Cap to LTM Revenue Psychedelic Medicine Levitee Labs (2) CSE: LVT 0.10 6,142,558 13,648,964 0.5x Field Trip Health TSX: FTRP 1.98 114,842,998 3,662,462 31.2x Numinus Wellness TSX: NUMI 0.59 121,545,74
Slide 24: Roadmap
ROADMAP HAVN RETAIL HAVN LABS Expand retail footprint for Natural Health First export of psilocybin from Jamaica Products in Canada and USA through additional to Canada and USA has validated supply chain Food, Drug, Mass and Specialty retailers First revenue from Supply Agreements Build subscriber b
Slide 25: Share Information and Capital Structure
SHARE INFORMATION AND CAPITAL STRUCTURE TRADING INFORMATION SHARE CAPITAL STRUCTURE FULLY DILUTED Trading Symbols CSE: HAVN / OTC: HAVLF / FRA: 5NP Common Shares O/S 148,757,315 (Basic) Cash on Hand CDN$ 2.1 million Dilutive Securities 52 week high/low CDN$ 0.85 / CDN$ 0.05 Stock Options 7,504,000 M
Slide 26: Collaboration Across Different Disciplines
COLLABORATION ACROSS DIFFERENT DISCIPLINES A team with deep experience in science, innovation, and product development Tim Moore Dr. Ivan Casselman Alexzander Samuelsson Gordon Clissold Jenna Pozar Juliana Mollica Chief Executive Officer Chief Psychedelic Officer Chief Research Officer Chief Financi
Slide 27: Accomplished Board of Directors
ACCOMPLISHED BOARD OF DIRECTORS Vic Neufeld Dr. David Mokler Allan Oberman Executive Chairman Advisor Advisor Former CEO of Aphria. Neuropharmacology, psychopharmacology, Former CEO for Concordia International. CEO of Jamieson Laboratories for 21 years, substance abuse, drug abuse, brain A pharmaceu
Slide 28: Thank You
The Future of Psychedelic Therapy THANK YOU IR@HAVNLIFE.com CSE: HAVN | FRA: 5NP | OTC: HAVLF
HAVN Life Sciences — Investor Presentation (April 2022) on 6ix